Insomnia Therapy

Research summary

• Cognitive behavioral therapy for insomnia (CBT-I) has the strongest randomized-trial base of any sleep intervention.
• A landmark 2015 meta-analysis of 20 RCTs found CBT-I significantly improved sleep onset latency, wake after sleep onset, and sleep efficiency versus inactive controls, and the American Academy of Sleep Medicine's 2021 systematic review and GRADE assessment (124 trials) confirmed benefit across several behavioral components (stimulus control, sleep restriction, relaxation, and multicomponent CBT-I).
• On this evidence, the American College of Physicians' clinical practice guideline recommends CBT-I as the initial treatment for all adults with chronic insomnia, ahead of medication.
• A 2024 JAMA Psychiatry component network meta-analysis of 241 trials (31,452 participants) confirmed efficacy across delivery formats, though it could not cleanly isolate which individual components drive the effect.
• Benefits extend beyond sleep: a meta-analysis of CBT-I in major depressive disorder with comorbid insomnia found it roughly doubled depression-response odds (OR 2.28, moderate-certainty evidence), and a 2025 JAMA Internal Medicine meta-analysis confirmed efficacy in people with chronic diseases such as cancer and cardiovascular disease.
• Effects on broader quality-of-life measures are less consistent than on core sleep symptoms, and combined treatments can carry modestly higher dropout.
• Overall, this is clinical-grade, guideline-backed evidence — the most rigorously validated intervention in this category.